MLYS - Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc. Common Stock Logo

MLYS - Mineralys Therapeutics, Inc. Common Stock

https://mineralystx.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bearish
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Bruker ( NASDAQ:BRKR ) , Alkermes ( NASDAQ:ALKS )
Benzinga • 1 week, 5 days ago • score: -0.29
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 150 points on Wednesday. Shares of Bruker Corp BRKR fell sharply in pre-market trading after the company announced a $600 million public offering. Bruker shares tumbled 9.8% to $29.98 in the pre-market ...
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The company is headquartered in Radnor, Pennsylvania.

52W High
$35.09
52W Low
$8.24
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
-0.30
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-7.41
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
8.61
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
1.10%
Institutions (25–75% balanced)
95.25%
Shares Outstanding
77,570,000
Float
44,458,900
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-3.56
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.63%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
7.7306
Previous
7.7190
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025